Forma Therapeutics Holdings, Inc.
FMTXDelisted Oct 14, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001538927
Forma Therapeutics Holdings, Inc. was delisted on Oct 14, 2022; its insiders filed their last Form 4 on Oct 14, 2022; 139 institutions reported holding it in 13F filings for Q3 2022, worth $835.0M in total; HHLR Advisors (Hillhouse) was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 139
- Q3 2022, +33 vs. previous quarter
- 13F value
- $835.0M
- Reported value at the end of Q3 2022
- Superinvestors holding
- 1
- At the end of Q3 2022
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2021
- $0
- No comparable prior period
- Net income, FY2021
- -$173.0M
- No comparable prior period
- Free cash flow, FY2021
- -$154.0M
- No comparable prior period
- Revenue, Q2 FY2022
- $0
- No comparable prior period
Superinvestors holding FMTX, Q3 2022
Go to the superinvestors tab1 superinvestor reports holding Forma Therapeutics Holdings, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
0.6%
Forma Therapeutics Holdings, Inc.'s share of the portfolio
- Shares
- 1,100,000
- Value
- $21.9M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Forma Therapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Cook David NSVP, Chief Scientific Officer | SSale | −3.53K | $9.78 | −$34.5K | −17.7%16.5K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Lee Frank D.President and CEO | SSale | −18.0K | $9.78 | −$175.9K | −18.4%79.8K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Kelly Patrick F.SVP, Chief Medical Officer | SSale | −5.25K | $9.78 | −$51.3K | −7.5%64.9K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Shegog ToddSVP, Chief Financial Officer | SSale | −5.69K | $9.78 | −$55.6K | −20.0%22.8K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Lesser Brian AndrewSVP, Commercial | SSale | −3.84K | $9.78 | −$37.5K | −17.9%17.6K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Wadlinger Mary E.See Remarks | SSale | −4.68K | $9.78 | −$45.8K | −3.4%134.5K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Potts JeannetteSee Remarks | SSale | −4.67K | $9.78 | −$45.7K | −17.3%22.4K after |
Top 10 13F holders, Q3 2022
See all 139 holdersThe largest institutional positions in Forma Therapeutics Holdings, Inc. at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,011,651 | $179.8M | 3.84% | 00.0% | Unchanged |
| BlackRock Inc. | 3,632,271 | $72.5M | 0.00% | +513,211+16.5% | Added |
| Baker Bros. Advisors LP | 1,886,760 | $37.6M | 0.25% | −138,116−6.8% | Reduced |
| Vanguard Group Inc | 1,865,281 | $37.2M | 0.00% | +220,012+13.4% | Added |
| TIG Advisors, LLC | 1,305,794 | $26.1M | 0.99% | +1,305,794 | New |
| Water Island Capital LLC | 1,253,785 | $25.0M | 1.42% | +1,253,785 | New |
| Alpine Associates Management Inc. | 1,140,500 | $22.8M | 0.95% | +1,140,500 | New |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,100,000 | $21.9M | 0.58% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,065,413 | $21.3M | 4.96% | −500,113−31.9% | Reduced |
| Vivaldi Asset Management, LLC | 1,029,333 | $20.5M | 0.97% | +1,029,333 | New |